一鸣食品(605179) - 2023 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2023 was CNY 578,449,077.96, representing a year-on-year increase of 3.98%[5] - The net profit attributable to shareholders for Q1 2023 was CNY 4,577,833.13, showing a significant increase of 111.46% compared to the same period last year[5] - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 2,941,608.80, reflecting a growth of 107.30% year-on-year[5] - The basic earnings per share for Q1 2023 was CNY 0.01, up by 111.42% year-on-year[6] - Net profit for Q1 2023 was CNY 4,577,833.13, a significant recovery from a net loss of CNY 39,952,048.24 in Q1 2022[19] Cash Flow - The net cash flow from operating activities for Q1 2023 was CNY 113,579,654.21, which is an increase of 56.26% compared to the previous year[6] - Operating cash flow for Q1 2023 was CNY 113,579,654.21, an increase from CNY 72,684,556.72 in Q1 2022[22] - The company reported a total cash inflow from operating activities of CNY 707,703,478.88, compared to CNY 721,228,043.50 in the previous year[22] - The net cash flow from investing activities was -35,082,232.88, compared to -98,495,436.49 in the previous period[23] - Cash inflow from financing activities totaled 10,000,000.00, down from 161,500,000.00 in the previous period[23] - The net cash flow from financing activities was -88,978,225.37, contrasting with a positive 14,395,071.03 in the previous period[23] - The cash and cash equivalents at the end of the period amounted to 170,175,389.47, down from 172,490,297.28[23] Assets and Liabilities - Total assets at the end of Q1 2023 were CNY 2,606,319,116.73, a decrease of 1.17% from the end of the previous year[6] - Total liabilities as of March 31, 2023, were CNY 1,248,191,188.56, down from CNY 1,290,172,324.95[15] - Short-term borrowings decreased to CNY 194,013,109.73 from CNY 219,041,373.62, a reduction of approximately 11.4%[15] - The total liabilities decreased to CNY 1,525,097,909.43 from CNY 1,560,507,062.56, a decline of 2.3%[18] - The total equity increased to CNY 1,081,221,207.30 from CNY 1,076,552,165.39, a growth of 0.4%[18] Expenses - Total operating costs decreased to CNY 574,881,030.35 from CNY 611,406,598.55, representing a reduction of 6.0%[18] - Research and development expenses for Q1 2023 were CNY 9,876,262.68, slightly down from CNY 10,082,821.58 in Q1 2022[18] - Sales expenses decreased by 36.49% due to the closure of loss-making stores in the previous year[9] - Sales expenses decreased to CNY 110,214,558.44 from CNY 173,545,378.84, a reduction of 36.5%[18] Assets Composition - Current assets totaled CNY 601,311,717.84, slightly down from CNY 607,053,914.90 in the previous period[14] - Cash and cash equivalents increased to CNY 330,471,745.80 from CNY 312,236,352.41[14] - Accounts receivable decreased to CNY 79,960,077.69 from CNY 98,298,223.17, indicating a reduction of approximately 18.5%[14] - Inventory rose to CNY 134,293,715.75 from CNY 127,416,440.53, reflecting an increase of about 5.9%[14] - Non-current assets totaled CNY 2,005,007,398.89, down from CNY 2,030,005,313.05[15] - The company reported a significant increase in production biological assets, rising to CNY 108,554,475.97 from CNY 97,481,557.26, an increase of about 11.0%[15] Other Information - The company reported a non-recurring gain of CNY 1,636,224.33 for the period, after accounting for tax effects[8] - The company has not reported any new product developments or market expansion strategies in this quarter[13] - The company did not apply new accounting standards or interpretations for the first quarter of 2023[24]